Tag: 300-400

On June 7, 2007, Naidu, Narasimhulu B.; Ueda, Yasutsugu; Connolly, Timothy P. published a patent.Name: 1-(Bromomethyl)-4-fluoro-2-iodobenzene The title of the patent was Preparation of pyrimidine derivatives as HIV integrase inhibitors. And the patent contained the following:

Title compounds I, wherein R1 is arylalkyl, arylamide, arylester, arylhydroxyalkyl or aryloxyalkyl; R2 is H, alkyl, hydroxy or alkoxy; R3 is (un)substituted methyl; R4 is alkyl are prepared as HIV integrase inhibitors. Thus, II was prepared and displayed and HIV-integrase inhibition between 0.002 to 0.10 渭M and an inhibition of HIV replication between 0.003 to 0.10 渭M. Further, I can successfully be employed as prodrugs for treatment of AIDS or HIV infection selected from the group consisting of nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors. The experimental process involved the reaction of 1-(Bromomethyl)-4-fluoro-2-iodobenzene(cas: 70931-59-8).Name: 1-(Bromomethyl)-4-fluoro-2-iodobenzene

The Article related to pyrimidine preparation hiv integrase inhibition human prodrug, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Name: 1-(Bromomethyl)-4-fluoro-2-iodobenzene

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

Kaneko, Yuzuru; Hayashi, Mimi; Agata, Hideharu; Ichinohe, Tatsuya; Kaneko, Yuzuru published an article in 2001, the title of the article was Propofol does not change the platelet retention rate.HPLC of Formula: 364-12-5 And the article contains the following content:

An acceleration of platelet aggregations during and after surgery increases the risks of perioperative myocardial or cerebral infarction. It has been reported that isoflurane and sevoflurane depress platelet aggregation, but there are no convincing reports about the effects of propofol. We therefore investigated the effect of propofol on platelet aggregation by determining the platelet retention rate (PRR). Twenty-six consenting oral surgical patients classified in ASA phys. status I were randomly assigned to one of two groups (GOS group: n=13; GOP group: n=13). The patients in the GOS group were induced with thiopental sodium, nasotracheally intubated with vecuronium bromide, and maintained with 60% nitrous oxide and 1.5% sevoflurane in oxygen. The patients in the GOP group were induced with propofol, nasotracheally incubated with vecuronium bromide, and maintained with 60% nitrous oxide and 10 mg/kg/h propofol in oxygen. The PRR was determined by the collagen bead column method. Venous blood was collected three times in each group for the determination of PRR. The first PRR was measured before the induction of anesthesia, the second PRR, after the induction of anesthesia, and the third PRR, 5 min after submucosal injection of 5 mL of 1% lidocaine solution containing epinephrine (1:100,000). Data were analyzed using one-way ANOVA for repeated measurements followed by Student-Newman-Keuls test for intragroup comparisons and Student’s t-test for unpaired samples for intergroup comparisons p values less than 0.05 indicated statistical significance. The PRR in the GOS group decreased after induction (36.4卤12.5%) and increased after local anesthesia (52.3卤17.0%) when compared with that before induction (45.2卤14.2%). The PRR in GOP group did not decrease after induction (43.0卤13.0%), but it also increased after local anesthesia (56.0卤12.9%) when compared with that before induction (42.1卤13.1%). These data were all within normal ranges. The PRR changes after induction were -8.7卤9.1% in GOS group and 0.8卤6.2% in GOP group, resp. (p<0.05 between two groups). In contrast, the PRR increased in both groups after local anesthesia (GOS group = 15.8卤9.6%; GOP group = 13.8卤12.8%). In conclusion, propofol has no or minimal effect on platelet aggregation. The inhibitory effects of sevoflurane and propofol on epinephrine-induced platelet aggregation may be similar. The experimental process involved the reaction of 5-Bromo-2-iodobenzotrifluoride(cas: 364-12-5).HPLC of Formula: 364-12-5

The Article related to propofol anesthetic platelet aggregation, Pharmacology: Effects Of Nervous System- and Behavior-Affecting Drugs and Neuromuscular Agents and other aspects.HPLC of Formula: 364-12-5

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On August 9, 1994, Tsucha, Kazuhiko; Sugiura, Atsushi; Suzuki, Kenji; Fujii, Tsunenori published a patent.Recommanded Product: 364-12-5 The title of the patent was Trifluoromethyl benzene derivative and liquid crystal composition containing same. And the patent contained the following:

The title trifluoromethyl-benzene derivative, 1-CF3-2-(AmR1)-5-(BnR2)-C6H3 [ R1, R2 = C1-14 alkyl, alkoxy, alkoxy-alkyl; A, B = phenylene, biphenylene, p-cyclohexyl phenylene, bicyclohexylene; m, n = 0, 1 ] is claimed. The title composition showed improved characteristics suitable for ferroelec. and nematic liquid crystal displays. The experimental process involved the reaction of 5-Bromo-2-iodobenzotrifluoride(cas: 364-12-5).Recommanded Product: 364-12-5

The Article related to liquid crystal composition trifluoromethyl benzene, lcd ferroelec nematic trifluoromethyl benzene, Radiation Chemistry, Photochemistry, and Photographic and Other Reprographic Processes: Other and other aspects.Recommanded Product: 364-12-5

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On July 26, 2021, Dorian, Andreas; Landgreen, Emily J.; Petras, Hayley R.; Shepherd, James J.; Williams, Florence J. published an article.Recommanded Product: 364-12-5 The title of the article was Iron-Catalyzed Halogen Exchange of Trifluoromethyl Arenes. And the article contained the following:

The facile production of ArCF2X and ArCX3 from ArCF3 using catalytic iron(III)halides is reported, which constitutes the first iron-catalyzed halogen exchange for non-aromatic C-F bonds. Theor. calculations suggest direct activation of C-F bonds by iron coordination. ArCX3 and ArCF2X products of the reaction are synthetically valuable due to their diversification potential. In particular, chloro- and bromodifluoromethyl arenes (ArCF2Cl, ArCF2Br resp.) provide access to a myriad of difluoromethyl arene derivatives (ArCF2R). To optimize for mono-halogen exchange, a statistical method called Design of Experiments was used. Optimized parameters were successfully applied to electron rich and electron deficient aromatic substrates, and to the late stage diversification of flufenoxuron, a com. insecticide. These methods are highly practical, being run at convenient temperatures and using inexpensive common reagents. The experimental process involved the reaction of 5-Bromo-2-iodobenzotrifluoride(cas: 364-12-5).Recommanded Product: 364-12-5

The Article related to ferric boron halide catalyzed halogen exchange trifluoromethyl arene, c鈭抐 activation, defluorination, halogen exchange, iron catalysis, late-stage modification, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Halides and Halonium Compounds and other aspects.Recommanded Product: 364-12-5

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On January 2, 2015, Shi, Guangfa; Shao, Changdong; Pan, Shulei; Yu, Jingxun; Zhang, Yanghui published an article.Computed Properties of 364-12-5 The title of the article was Silver-Catalyzed C-H Trifluoromethylation of Arenes Using Trifluoroacetic Acid as the Trifluoromethylating Reagent. And the article contained the following:

Direct trifluoromethylation of arenes using TFA as the trifluoromethylating reagent was achieved with Ag as the catalyst. This reaction not only provides a new protocol for aryl C-H trifluoromethylation, but the generation of CF3路 from TFA may prove useful in other contexts and could potentially be extended to other trifluoromethylation reactions. The experimental process involved the reaction of 5-Bromo-2-iodobenzotrifluoride(cas: 364-12-5).Computed Properties of 364-12-5

The Article related to silver catalyst trifluoromethylation arene trifluoroacetic acid, carbon hydrogen bond activation green chem, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Halides and Halonium Compounds and other aspects.Computed Properties of 364-12-5

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On September 6, 2012, Flynn, Daniel L.; Kaufman, Michael D. published a patent.HPLC of Formula: 1012882-90-4 The title of the patent was Preparation of heterocyclic urea derivatives as kinase inhibitors useful for the treatment of hyperproliferative and other diseases. And the patent contained the following:

Compounds of the present invention (I, wherein E1 is substituted phenyl; A is substituted pyrazolyl and imidazolyl; X2 is a direct bond, wherein E1 is directly linked to the NH group; X3 is -O-; Z6 is independently and individually selected from H, C1-6 alkyl, branched C3-7 alkyl, hydroxy, etc.; t = 1-3), alone and in combination with other active agents, find utility in the treatment of hyperproliferative diseases, mammalian cancers and especially human cancers including but not limited to for example malignant melanomas, myeloproliferative diseases, chronic myelogenous leukemia, acute lymphocytic leukemia, a disease caused by c-ABL kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof. More generally the invention relates to a method of treating mammalian disease with I wherein the disease etiol. or progression is at least partially mediated by the kinase activity of c-ABL kinase, BCR-ABL kinase, FLT-3 kinase, TIE-2 kinase, TRK-A kinase, TRK-B kinase, TRK-C kinase, VEGFR-2 kinases, c-MET kinase, PDGFR-alpha kinase, PDGFR-beta kinase, HER-1 kinase, HER-2 kinase, HER-3 kinase, HER-4 kinase, FGFR kinases, c-KIT kinase, RET kinase, c-FMS kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs of any of the foregoing. Synthetic procedures for preparing I are exemplified. Thus, e.g., II was prepared by coupling of 2,2,2-trichloroethyl 3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-ylcarbamate (preparation given) with 4-(4-amino-3-fluorophenoxy)-N-methylpicolinamide (preparation given). Assays were described for evaluating binding of I to various kinases, e.g., II demonstrated an IC50 value of 4 nM in the p-Abl kinase assay. The experimental process involved the reaction of Ethyl 5-chloro-2-iodobenzoate(cas: 1012882-90-4).HPLC of Formula: 1012882-90-4

The Article related to preparation heterocyclic urea derivative kinase inhibitor treatment hyperproliferative disease, Aliphatic Compounds: Ureas, Carbamic Acids, Guanidines, and Their Sulfur-Containing Analogs and other aspects.HPLC of Formula: 1012882-90-4

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On March 14, 2013, Flynn, Daniel L.; Petillo, Peter A.; Kaufman, Michael D. published a patent.Recommanded Product: 1012882-90-4 The title of the patent was Preparation of heterocyclic urea derivatives as kinase inhibitors useful for the treatment of myeloproliferative diseases and other proliferative diseases. And the patent contained the following:

Compounds of the invention (I, wherein E1 is substituted phenyl; A is substituted pyrazolyl and imidazolyl; X2 is a direct bond, wherein E1 is directly linked to the NH group; X3 is -O-; Z6 is independently and individually selected from H, C1-6 alkyl, branched C3-7 alkyl, hydroxy, etc.; t = 1-3) find utility in the treatment of of cancer, secondary cancer growth arising from metastasis, hyperproliferative diseases, diseases characterized by hyper-vascularization, inflammation, osteoarthritis, respiratory diseases, stroke, systemic shock, immunol. diseases, autoimmune diseases, bone resorptive diseases, cardiovascular disease and diseases characterized by angiogenesis. The invention also provides a method of modulating a kinase activity of a wild-type kinase species, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs of any of the foregoing, by contacting said species with a compound I. Synthetic procedures for preparing I are exemplified. Thus, e.g., II was prepared by coupling of 2,2,2-trichloroethyl 3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-ylcarbamate (preparation given) with 4-(4-amino-3-fluorophenoxy)-N-methylpicolinamide (preparation given). Assays were described for evaluating binding of I to various kinases, e.g., II demonstrated an IC50 value of 4 nM in the p-Abl kinase assay. The experimental process involved the reaction of Ethyl 5-chloro-2-iodobenzoate(cas: 1012882-90-4).Recommanded Product: 1012882-90-4

The Article related to preparation heterocyclic urea derivative kinase inhibitor treatment myeloproliferative disease, Aliphatic Compounds: Ureas, Carbamic Acids, Guanidines, and Their Sulfur-Containing Analogs and other aspects.Recommanded Product: 1012882-90-4

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On September 7, 2010, Flynn, Daniel L.; Petillo, Peter A.; Kaufman, Michael D. published a patent.Electric Literature of 1012882-90-4 The title of the patent was Preparation of urea derivatives as kinase inhibitors useful for the treatment of myeloproliferative diseases and other proliferative diseases. And the patent contained the following:

Title compounds I [E1 = (un)substituted Ph; A = (un)substituted imidazolyl or pyrazolyl; X2 = bond; X3 = O; each R3 independently = H, alkyl, carbocyclyl, etc.; each Z6 independently = H, alkyl, hydroxyalkyl, etc.; m = 1-3] are prepared and disclosed for treatment of myeloproliferative diseases and other proliferative diseases. Thus, e.g., II was prepared by coupling of 2,2,2-trichloroethyl 3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-ylcarbamate (preparation given) with 4-(4-amino-3-fluorophenoxy)-N-methylpicolinamide (preparation given). Select I were evaluated in Abl kinase and T315I Abl kinase assays (data given). The experimental process involved the reaction of Ethyl 5-chloro-2-iodobenzoate(cas: 1012882-90-4).Electric Literature of 1012882-90-4

The Article related to urea derivative preparation myeloproliferative proliferative disease, Aliphatic Compounds: Ureas, Carbamic Acids, Guanidines, and Their Sulfur-Containing Analogs and other aspects.Electric Literature of 1012882-90-4

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On April 17, 2008, Petillo, Peter A.; Kaufman, Michael D.; Flynn, Daniel L. published a patent.COA of Formula: C9H8ClIO2 The title of the patent was Preparation of urea derivatives as kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases. And the patent contained the following:

Title compounds I [Q1 and Q2 independently = N or CZ6; E1 = cycloalkyl, pyrrolidinyl, piperidinyl, etc.; A = (un)substituted Ph, furyl, thienyl, etc.; X2 = alkyl or bond; X3 = CO, O, (un)substituted alkoxy, etc.; R3 independently = H, alkyl, carbocyclyl, and substituted phenyl; Z6 independently = H, alkyl, OH, hydroxyalkyl, etc.; m = 1-3] are prepared and disclosed for treatment of hyperproliferative diseases and mammalian cancers, especially human cancers. Thus, e.g., II was prepared by coupling of 2,2,2-trichloroethyl 3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-ylcarbamate (preparation given) with 4-(4-amino-3-fluorophenoxy)-N-methylpicolinamide (preparation given). Assays were described for evaluating binding of I to various kinases, e.g., II demonstrated an IC50 value of 4 nM in the p-Abl kinase assay. The invention also pertains to methods of modulating kinase activities, pharmaceutical compositions, and methods of treating individuals, incorporating or using the compounds The experimental process involved the reaction of Ethyl 5-chloro-2-iodobenzoate(cas: 1012882-90-4).COA of Formula: C9H8ClIO2

The Article related to urea derivative preparation kinase inhibitor, Aliphatic Compounds: Ureas, Carbamic Acids, Guanidines, and Their Sulfur-Containing Analogs and other aspects.COA of Formula: C9H8ClIO2

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

Linsenmeier, Anna M.; Williams, Craig M.; Brase, Stefan published an article in 2013, the title of the article was Photochemical Synthesis of Phenanthridines: Exploring Fluoro and Protected Catechol Substitution.Name: 1-(Bromomethyl)-4-fluoro-2-iodobenzene And the article contains the following content:

Substituted phenanthridines, such as the natural product trispheridine, have been accessed by the practical photochem. cyclization of N-benzylanilines. Functionalities, with a focus on fluoro substituents and protected catechols, are well tolerated on both the A and C rings. The phenanthridines were accessed in good to very good yields (up to 95 %) from iodinated substrates, whereas brominated substrates performed poorly in comparison (0-48 %). The experimental process involved the reaction of 1-(Bromomethyl)-4-fluoro-2-iodobenzene(cas: 70931-59-8).Name: 1-(Bromomethyl)-4-fluoro-2-iodobenzene

The Article related to iodobenzylaniline fluoro protected catechol containing photochem cyclization, phenanthridine preparation, Heterocyclic Compounds (One Hetero Atom): Other Areno- and Diarenopyridines (Acridines, Quinolizines, etc.) and other aspects.Name: 1-(Bromomethyl)-4-fluoro-2-iodobenzene

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com